✦ LIBER ✦

Immunotherapy of type 1 diabetes — How to rationally prioritize combination therapies in T1D

✍ Scribed by Tobias Boettler; Matthias von Herrath

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy with sitagliptin and

✍ Griffin, Kurt J; Thompson, Paul A; Gottschalk, Michael; Kyllo, Jennifer H; Rabin 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 388 KB

RM1 Real-World Evidence on the Effects o

✍ B.J. Borah; N. Shah; M. Reinalda; V. Montori 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Fixed-dose combination therapies in the

✍ G. Schernthaner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Combination of KIR 2DL2 and HLA-C1 (Asn8

✍ A. Shastry; S. K. Sedimbi; R. Rajalingam; L. Nikitina-Zake; I. Rumba; H. Wigzell 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB

Fel d 1-derived T cell peptide therapy i

✍ C. Alexander; S. Ying; A. B. Kay; M. Larché 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 780 KB

PDB5 LONG-TERM CONSEQUENCES FOR THE TREA

✍ S Maxion-Bergemann; W Wittenberg; R Bergemann 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB